Vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. Reuters/File
• Cansino Bio only company to have conducted clinical trials in Pakistan
• Around 20m doses to be available in next six months
• Another Chinese firm to conduct clinical trial
ISLAMABAD: The Drug Regulatory Authority of Pakistan (Drap) on Friday issued emergency use authorisation to the Chinese company Cansino Biologics Inc’s Covid-19 vaccine after which supply of the doses will start in a few weeks.